Structure-based ligand design to overcome CYP inhibition in drug discovery projects.
Branden, G., Sjogren, T., Schnecke, V., Xue, Y.(2014) Drug Discov Today 19: 905-911
- PubMed: 24642031 
- DOI: 10.1016/j.drudis.2014.03.012
- Primary Citation of Related Structures:  
- PubMed Abstract: 
Cytochrome P450 (CYP) enzymes are key players in xenobiotic metabolism, and inhibition of CYPs can therefore result in unwanted drug-drug interactions. Within drug discovery, CYP inhibition can cause delays in the progression of candidate drugs, or e ...